Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Shares Outstanding (Diluted Average) (2017 - 2025)

Historic Shares Outstanding (Diluted Average) for Arrowhead Pharmaceuticals (ARWR) over the last 12 years, with Q4 2025 value amounting to $140.7 million.

  • Arrowhead Pharmaceuticals' Shares Outstanding (Diluted Average) rose 1270.18% to $140.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $140.7 million, marking a year-over-year increase of 1270.18%. This contributed to the annual value of $133.8 million for FY2025, which is 1166.6% up from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Shares Outstanding (Diluted Average) stood at $140.7 million for Q4 2025, which was up 1270.18% from $133.8 million recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' Shares Outstanding (Diluted Average)'s 5-year high stood at $140.7 million during Q4 2025, with a 5-year trough of $103.7 million in Q3 2021.
  • For the 5-year period, Arrowhead Pharmaceuticals' Shares Outstanding (Diluted Average) averaged around $115.5 million, with its median value being $107.7 million (2022).
  • In the last 5 years, Arrowhead Pharmaceuticals' Shares Outstanding (Diluted Average) increased by 19.83% in 2023 and then skyrocketed by 1622.96% in 2024.
  • Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $104.5 million in 2021, then rose by 1.44% to $106.0 million in 2022, then grew by 1.3% to $107.4 million in 2023, then grew by 16.23% to $124.8 million in 2024, then increased by 12.7% to $140.7 million in 2025.
  • Its last three reported values are $140.7 million in Q4 2025, $133.8 million for Q3 2025, and $139.0 million during Q2 2025.